The Impact of Clinical Factors on the Development of Late Radiation Toxicity: Results from the Medical Research Council RT01 Trial (ISRCTN47772397)

被引:93
作者
Barnett, G. C. [1 ,2 ]
De Meerleer, G. [3 ]
Gulliford, S. L. [4 ,5 ]
Sydes, M. R. [6 ]
Elliott, R. M. [7 ]
Dearnaley, D. P. [8 ]
机构
[1] Univ Cambridge, Cambridge Univ Hosp NHS Fdn Trust, Ctr Oncol, Dept Oncol, Cambridge, England
[2] Strangeways Res Lab, Dept Oncol, Cambridge CB1 8RN, England
[3] Ghent Univ Hosp, Dept Radiat Oncol, B-9000 Ghent, Belgium
[4] Inst Canc Res, Joint Dept Phys, Sutton, Surrey, England
[5] Royal Marsden NHS Fdn Trust, Sutton, Surrey, England
[6] MRC Clin Trials Unit, Canc Grp, London, England
[7] Univ Manchester, Christie Hosp, Sch Canc & Enabling Sci, Manchester, Lancs, England
[8] Inst Canc Res, Dept Acad Urol, Sutton, Surrey, England
基金
英国医学研究理事会;
关键词
Adverse effects; multivariate analysis; prostate cancer; radiotherapy; toxicity; LOCALIZED PROSTATE-CANCER; INTENSITY-MODULATED RADIOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; DOSE CONFORMAL RADIOTHERAPY; EXTERNAL-BEAM RADIOTHERAPY; COMPARING; 68; GY; MRC RT01; RECTAL TOXICITY; NORMAL TISSUE; ESCALATION;
D O I
10.1016/j.clon.2011.03.001
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Aims: A variety of dosimetric parameters have been shown to influence the incidence of late radiation toxicity. The effect of other treatment- and patient-related factors is less well established. The aim of this study was to elucidate the influence of such factors in the development of late symptoms after radical radiotherapy to the prostate. Materials and methods: Patient- and treatment-related factors that are thought to influence the development of late toxicity were analysed in 788 patients who had received radical radiotherapy to the prostate in the Medical Research Council RT01 trial. Late toxicity data were recorded using the Radiation Therapy Oncology Group, Late Effects of Normal Tissues/Subjective, Objective, Management, Analytic, Royal Marsden Hospital and the University of California, Los Angeles, Prostate Cancer Index. Acute toxicity was measured using the Radiation Therapy Oncology Group grading system. Results: On multivariate analysis, acute bowel toxicity was statistically significantly associated with increased proctitis (hazard ratio=1.63, 95% confidence interval 1.18, 2.24; P=0.003) and increased stool frequency (hazard ratio=1.77, 95% confidence interval 1.27, 2.46; P =0.001).Hypertension was strongly associated with a decreased risk of poor urinary stream (hazard ratio=0.25, 95% confidence interval 0.09, 0.71; P=0.009). There was an increased risk of rectal bleeding with increased age (hazard ratio=1.04 per year of age, 95% confidence interval 1.01, 1.08; P=0.009). As expected, a higher prescribed dose increased the risk of several late toxicity end points. Although acute bladder toxicity was associated with the presence of bladder symptoms at 5 years, the effect disappeared for all symptoms except increased urinary frequency and haematuria when a change in bladder function from baseline was calculated. Patients with any pretreatment bladder symptoms were more likely to report increased urinary frequency (hazard ratio=2.09, 95% confidence interval 1.48, 2.95; P<0.0005), increased urinary incontinence (hazard ratio=4.22, 95% confidence interval 2.13. 8.35; P < 0.0005) and decreased stream (hazard ratio=2.64, 95% confidence interval 1.62, 4.31; P<0.0005), after treatment and before the most recent follow-up assessment. Conclusions: In this study, increased acute gastrointestinal and bladder symptoms and prescribed dose were associated with increased late radiation toxicity. The presence of hypertension seemed to be protective for the development of late effects. Baseline symptoms should be taken into account when radiation toxicity is analysed. (C) 2011 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:613 / 624
页数:12
相关论文
共 55 条
[1]
ROLE OF INTENSITY-MODULATED RADIOTHERAPY IN REDUCING TOXICITY IN DOSE ESCALATION FOR LOCALIZED PROSTATE CANCER [J].
Al-Mamgani, Abrahim ;
Heemsbergen, Wilma D. ;
Peeters, Stephanif T. H. ;
Lebesque, Joos V. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (03) :685-691
[2]
Bentzen, 1994, Semin Radiat Oncol, V4, P68, DOI 10.1016/S1053-4296(05)80034-7
[3]
CLINICAL CORRELATIONS BETWEEN LATE NORMAL TISSUE END-POINTS AFTER RADIOTHERAPY - IMPLICATIONS FOR PREDICTIVE ASSAYS OF RADIOSENSITIVITY [J].
BENTZEN, SM ;
OVERGAARD, M ;
OVERGAARD, J .
EUROPEAN JOURNAL OF CANCER, 1993, 29A (10) :1373-1376
[4]
Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology [J].
Bentzen, Soren M. .
NATURE REVIEWS CANCER, 2006, 6 (09) :702-713
[5]
Burnet N G, 1996, Clin Oncol (R Coll Radiol), V8, P25, DOI 10.1016/S0936-6555(05)80035-4
[6]
Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: Toxicity and biochemical outcomes [J].
Cahlon, Oren ;
Zelefsky, Michael J. ;
Shippy, Alison ;
Chan, Heather ;
Fuks, Zvi ;
Yamada, Yoshiya ;
Hunt, Margie ;
Greenstein, Steven ;
Amols, Howard .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 71 (02) :330-337
[7]
Cancer Research UK, CANCERSTATS
[8]
Delayed rectal and urinary symptomatotogy in patients treated for prostate cancer by radiotherapy with or without short term neo-adjuvant androgen deprivation [J].
Christie, D ;
Denham, J ;
Steigler, A ;
Lamb, D ;
Turner, S ;
Mameghan, H ;
Joseph, D ;
Matthews, J ;
Franklin, I ;
Atkinson, C ;
North, J ;
Poulsen, M ;
Spry, NA ;
Tai, KH ;
Wynne, C ;
Duchesne, G ;
Kovacev, O ;
Francis, L ;
Kramar, A ;
D'Este, C ;
Bill, D .
RADIOTHERAPY AND ONCOLOGY, 2005, 77 (02) :117-125
[9]
Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial [J].
Dearnaley, David P. ;
Sydes, Matthew R. ;
Graham, John D. ;
Aird, Edwin G. ;
Bottomley, David ;
Cowan, Richard A. ;
Huddart, Robert A. ;
Jose, Chakiath C. ;
Matthews, John H. L. ;
Millar, Jeremy ;
Moore, A. Rollo ;
Morgan, Rachel C. ;
Russell, J. Martin ;
Scrase, Christopher D. ;
Stephens, Richard J. ;
Syndikus, Isabel ;
Parmar, Mahesh K. B. .
LANCET ONCOLOGY, 2007, 8 (06) :475-487
[10]
The early toxicity of escalated versus standard dose conformal radiotherapy with neo-adjuvant androgen suppression for patients with localised prostate cancer: Results from the MRC RT01 trial (ISRCTN47772397) [J].
Dearnaley, David P. ;
Sydes, Matthew R. ;
Langley, Ruth E. ;
Graham, John D. ;
Huddart, Robert A. ;
Syndikus, Isabel ;
Matthews, John H. L. ;
Scrase, Christopher D. ;
Jose, Chakiath C. ;
Logue, John ;
Stephens, Richard J. .
RADIOTHERAPY AND ONCOLOGY, 2007, 83 (01) :31-41